K
Kristoffer Staal Rohrberg
Researcher at University of Copenhagen
Publications - 52
Citations - 1065
Kristoffer Staal Rohrberg is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 10, co-authored 29 publications receiving 506 citations. Previous affiliations of Kristoffer Staal Rohrberg include Copenhagen University Hospital.
Papers
More filters
Journal ArticleDOI
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong,Steven G. DuBois,Shivaani Kummar,Anna F. Farago,Catherine M. Albert,Kristoffer Staal Rohrberg,Cornelis M. van Tilburg,Cornelis M. van Tilburg,Ramamoorthy Nagasubramanian,Jordan Berlin,Noah Federman,Leo Mascarenhas,Birgit Geoerger,Afshin Dowlati,Alberto S. Pappo,Stefan S. Bielack,François Doz,Ray McDermott,Jyoti D. Patel,Russell J. Schilder,Makoto Tahara,Stefan M. Pfister,Stefan M. Pfister,Olaf Witt,Olaf Witt,Marc Ladanyi,Erin R. Rudzinski,Shivani Nanda,Barrett H. Childs,Theodore W. Laetsch,David M. Hyman,David M. Hyman,Alexander Drilon,Alexander Drilon +33 more
TL;DR: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active and indicate that long-term administration of larot rectinib are feasible.
Journal ArticleDOI
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results
Padmanee Sharma,Arlene O. Siefker-Radtke,Filippo de Braud,Umberto Basso,Emiliano Calvo,Petri Bono,Michael A. Morse,Paolo A. Ascierto,Jose A. Lopez-Martin,Peter Brossart,Kristoffer Staal Rohrberg,Begoña Mellado,Bruce S. Fischer,S. Meadows-Shropshire,Abdel Saci,Margaret K. Callahan,Margaret K. Callahan,Jonathan E. Rosenberg,Jonathan E. Rosenberg +18 more
TL;DR: NIVO1+IPI3 provided the greatest antitumor activity of all regimens, with a manageable safety profile, and this result not only supports additional study of NIVO3 in mUC, but demonstrates the potential benefit of immunotherapy combinations in this disease.
Journal ArticleDOI
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
Birgitte Bertelsen,Ida Viller Tuxen,Christina Westmose Yde,Migle Gabrielaite,Mathias H. Torp,Savvas Kinalis,Olga Oestrup,Kristoffer Staal Rohrberg,Iben Spangaard,Eric Santoni-Rugiu,Karin Wadt,Morten Mau-Sørensen,Ulrik Lassen,Finn Cilius Nielsen +13 more
TL;DR: A high frequency of pathogenic germline variants in the homologous recombination pathway in patients with advanced solid cancers is demonstrated, infering that genetic screening in this group of patients may reveal high-risk families and identify patients with potential PARP inhibitor sensitive tumors.
Journal ArticleDOI
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Ida Viller Tuxen,Kristoffer Staal Rohrberg,Olga Oestrup,Lise Barlebo Ahlborn,Ane Y. Schmidt,Iben Spanggaard,Jane Preuss Hasselby,Eric Santoni-Rugiu,Christina Westmose Yde,Morten Mau-Sørensen,Finn Cilius Nielsen,Ulrik Lassen +11 more
TL;DR: This study supports the feasibility of genomic profiling to select patients in the phase I setting and suggests that genomic matching can be beneficial for a minor subset of patients with no other treatment options and Randomized studies may validate this assumption.
Journal ArticleDOI
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Antje Wick,Oliver Bähr,Martin Schuler,Kristoffer Staal Rohrberg,Sant P. Chawla,Filip Janku,David Schiff,Volker Heinemann,Yoshitaka Narita,Heinz-Josef Lenz,Masafumi Ikeda,Yuichi Ando,Wolfgang Wick,Joachim P. Steinbach,Michael C. Burger,Katharina J. Wenger,Ulrik Lassen,Kamalesh Kumar Sankhala,Cristiana Roggia,Isabelle Genvresse,Catya Munhoz,Christine Rentzsch,Susanne Reschke,Simon Langer,Markus Wagner,Stefan Kaulfuss,Charles Cai,Eleni Lagkadinou,Michael Jeffers,Carol Peña,Ghazaleh Tabatabai +30 more
TL;DR: The first-in-human study was designed to determine the safety and pharmacokinetics of BAY1436032, and to evaluate its potential pharmacodynamics and antitumor effects as mentioned in this paper.